Search

Your search keyword '"Kamm, Y.J.L."' showing total 10 results
Start Over Author "Kamm, Y.J.L."
10 results on '"Kamm, Y.J.L."'

3. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial

Author

Tjan-Heijnen, Vivianne C G, primary, van Hellemond, Irene E G, additional, Peer, Petronella G M, additional, Swinkels, Astrid C P, additional, Smorenburg, Carolien H, additional, van der Sangen, Maurice J C, additional, Kroep, Judith R, additional, De Graaf, Hiltje, additional, Honkoop, Aafke H, additional, Erdkamp, Frans L G, additional, van den Berkmortel, Franchette W P J, additional, de Boer, Maaike, additional, de Roos, Wilfred K, additional, Linn, Sabine C, additional, Imholz, Alexander L T, additional, Seynaeve, Caroline M, additional, Kitzen, J.J.E.M., additional, Strobbe, L.J.A., additional, Kouwenhoven, E.A., additional, van Dalen, T., additional, van Overbeeke, A.J., additional, Nuytinck, J.K.S., additional, Arntz, I.E., additional, Blaisse, R.J.B., additional, Stockmann, H.B.A.C., additional, Nijhuis, P.H.A., additional, Veldhuis, G.J., additional, Mastboom, W.J.B., additional, van Riel, J.M.G.H., additional, van Dam, J.H., additional, den Boer, M.O., additional, Agterof, M.J., additional, de Roos, M.A.J., additional, Roumen, R.M.H., additional, van der Hoeven, J.J.M., additional, Beeker, A., additional, Koelemij, R., additional, van Bochove, A., additional, Madretsma, G.S., additional, Siemerink, E.J.M., additional, Guicherit, O.R., additional, Vos, A.H., additional, Nieuwenhuijzen, G.A.P., additional, Kehrer, D.F.S., additional, Valster, F.A.A., additional, Tanis, B.C., additional, van Voorthuizen, T., additional, van der Velden, A.M.T., additional, Hellingman, R.A., additional, Vree, R., additional, van Rossum-Schornagel, Q., additional, Meerum Terwogt, J.M., additional, van Leeuwen-Breuk, W.G., additional, Haasjes, J.G., additional, Davidis-van Schoonhoven, M.A., additional, Vriens, E.J.C., additional, Jagers, M., additional, Muller, E.W., additional, Schiphorst, P.P.J.B.M., additional, van Groeningen, C.J., additional, van Dijk, M.A., additional, Janssens- van Vliet, E., additional, Schepers, E.E.M., additional, Merkus, J.W.S., additional, van Diemen, N.G.J., additional, van Doorn, R.C., additional, Bosscha, K., additional, den Toom, R., additional, van der Velden, P.C., additional, van Rossum, C.T.A.M., additional, Oosterkamp, H.M., additional, van Hillegersberg, R., additional, Jas, B., additional, Weernink, E.E.M., additional, Ketel, J.M.A., additional, Jansen, J.J., additional, Maring, J.K., additional, Govaert, M.J.P.M., additional, Kamm, Y.J.L., additional, Vleugel, M.M., additional, Hovenga, S., additional, de Boer, J., additional, Potthoff, H., additional, Sommeijer, D.W., additional, and van Dulken, E.J., additional

Published
2017
Full Text
View/download PDF

4. In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength

Author

Laarhoven, H.W.M. van, Klomp, D.W.J., Kamm, Y.J.L., Punt, C.J.A., and Heerschap, A.

Subjects
Functional Imaging [UMCN 1.1]
Abstract

Item does not contain fulltext In metastatic colorectal cancer the oral 5-fluorouracil (5FU) prodrug capecitabine is used with increasing frequency as an alternative to i.v. 5FU administration. The rate of conversion of capecitabine into 5'deoxy-5-fluorouridine has been related to tumor response, and 5FU catabolites have been associated with 5FU-related systemic toxicity. Here we demonstrate for the first time that capecitabine, its metabolites 5'deoxy-5-fluorocytidine and 5'deoxy-5-fluorouridine, and its catabolites 5-fluoro-ureido-propionic acid, alpha-fluoro-beta-alanine, and alpha-fluoro-beta-alanine-bile acid conjugate can be monitored in vivo by (19)fluorine magnetic resonance spectroscopy ((19)F MRS) in the liver of patients with metastatic colorectal cancer. Moreover, we demonstrate an improved signal-to-noise ratio and spectral resolution of the (19)F MRS spectra when measurements are performed at 3 T field strength as compared with measurements at the common clinical field strength of 1.5 T. We conclude that assessment of capecitabine metabolism in patients by (19)F MRS is a promising noninvasive tool for the prediction of its efficacy and toxicity, especially at the now currently available clinical field strength of 3 T.

Published
2003

5. 19F magnetic resonance spectroscopy of 5-fluorouracil in the treatment of colorectal cancer

Author

Kamm, Y.J.L., Wagener, D.J.T., Heerschap, A., Rietjens, I.M.C.M., and Radboud University Nijmegen

Subjects
Experimental diagnostics and therapy of malignancies, Biomedische Magnetische Resonantie, Biomedical Magnetic Resonance
Abstract

Item does not contain fulltext KUN, 12 oktober 2001 Promotores : Wagener, D.J.T., Heerschap, A., Rietjens, I.M.C.M.

Published
2001

10. Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model.

Author

van Halteren, H.K., Bongaerts, G.P.A., Verhagen, C.A.M., Kamm, Y.J.L., Willems, J.L., Grutters, G.J., Koopman, J.P., and Wagener, D.J.Th.

Subjects
TUMORS, ANAEROBIC infections, GLUCOSE, METABOLISM, ERYTHROPOIETIN, THERAPEUTICS
Abstract

Background: Within hypoxic tumor regions anaerobic dissimilation of glucose is the sole source of energy generation. It yields only 5% of the ATP that is normally gained by means of oxidative glucose catabolism. The increased need for glucose may aggravate cancer cachexia. We investigated the impact of recombinant human erythropoietin (RhEPO) and increased inspiratory oxygen concentrations on weight loss in tumor-bearing mice. Methods: Fragments of the murine C26-B adenocarcinoma were implanted in 60 BALB/c-mice. The mice were divided into four groups and assigned to: (A) no treatment; (B) RhEPO- administration (25 IU daily from day 1-11, three times per week from day 12); (C) RhEPO and 25% oxygen; and (D) RhEPO and 35% oxygen. Three control groups of four healthy mice each received the same treatment as groups A, B, and D, respectively. Hematocrit and hemoglobin levels, tumor volume, and body weight were monitored. At day 17 the experiment was terminated and the serum lactate concentration was measured. The tumors were excised and weighed and, for each mouse, the percentage weight loss was calculated. The impact of tumor weight and the treatments on lactate concentration and weight loss was evaluated. Results: Significant positive correlations were found between tumor weight and lactate concentration and between tumor weight and percentage weight loss. In the mice with the largest tumors, RhEPO displayed a significant weight loss-reducing effect, and a significant negative correlation was found between hemoglobin concentration and weight loss. An oxygen-rich environment did not appear to influence weight loss. Conclusion: Anaerobic glycolysis in a growing C26-B tumor is related to weight loss. RhEPO administration results in a reduction of the percentage weight loss; this effect is probably mediated by an increased hemoglobin concentration. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results